Biopharma dealmakers had tempered their excitement heading into last year. Stuart Cable, global chair of M&A at Goodwin, said he'll be keeping a close eye on antitrust issues like the ones Roche ran into while acquiring the gene therapy developer Spark Therapeutics. Lisa Haddad, co-chair of the public M&A and corporate governance practice at Goodwin, expects SPACs to continue to be on fire. Read the BioPharma Dive article here.
In The Press January 13, 2021